Vena cava filters and inferior vena cava thrombosis  by Corriere, Matthew A. et al.
From the Society for Clinical Vascular Surgery
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Objective:Retrievable vena cava filters (R-VCF) are a recent addition to the therapeutic armamentarium for the prevention
of pulmonary embolism. However, unlike permanent vena cava filters (P-VCF), outcomes data are limited regarding
complication rates.
Methods: This was a retrospective comparative analysis of consecutive patients undergoing placement of R-VCF vs P-VCF
at Wake Forest University School of Medicine from January 2000 to December 2004. Data collected included
demographics, procedural specifics, filter type, indications, and complications. Summary data are expressed as number
(percentage) or mean  SD. Continuous and categorical variables were analyzed by using t and Fisher exact testing, as
appropriate. Four additional patients with vena cava thrombosis were also referred to our institution for treatment
during the study period, all with opposed biconical VCFs (OptEase and TrapEase filters) recently placed at other facilities.
This last group of patients is described but not included in the analysis.
Results: A total of 189 VCF (165 P-VCF and 24 R-VCF) cases were examined. No significant differences in VCF groups
were observed according to age, documented hypercoagulability, or concomitant anticoagulation. Significant differences
were observed according to sex (30.3% of P-VCF vs 62.5% of R-VCF patients were female), morbid obesity (4.2% of
P-VCF vs 25% of R-VCF patients), active malignancy (20% of P-VCF vs 41.7% of R-VCF patients), and indication for
VCF placement. Over a median follow-up of 8.5 months, no case of significant hemorrhage, no VCF migration, and four
cases of vena cava thrombosis were observed. Vena cava thrombosis was observed more frequently in the presence of
R-VCF when compared with P-VCF (12.5% vs 0.6%; P .007). All observed vena cava thromboses were associated with
severe clinical symptoms and occurred in patients who received opposed biconical VCF designs.
Conclusions: In our experience, both P-VCF and R-VCF can be placed safely. Among both permanent and retrievable
devices, however, opposed biconical designs seem to be associated with an increased risk for vena cava thrombosis.
Although causative factors remain unclear, filter design and resultant flow dynamics may play an important role, because
all episodes of vena cava thrombosis occurred in patients with a single-filter design. (J Vasc Surg 2007;45:789-94.)Deep venous thrombosis (DVT) and pulmonary embo-
lism (PE) are common causes of in-hospital and long-term
morbidity and mortality. Venous thromboembolism (VTE)
affects 104 to 117 per 100,000 persons in the United
States,1,2 with an estimated 275,000 n e w cases of PE ac-
counting for approximately 50,000 deaths annually.3,4 An-
ticoagulation is the first-line treatment for DVT and PE.5
However, in certain patients anticoagulation is either con-
traindicated or ineffective, and in such patients PE prophy-
laxis using vena cava interruption filters (VCF) is the treat-
ment of choice. Initial VCFs were designed for permanent
implantation (permanent vena cava filter; P-VCF). Many
patients requiring VCF have either a finite period of risk for
PE or contraindications to anticoagulation that are self-
limited, and removable vena cava filters (R-VCF) have been
developed, approved, and promoted for use in such pa-
tients. Despite the lack of level I data supporting their use
relative to P-VCF and limited follow-up experience, R-
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doi:10.1016/j.jvs.2006.12.048VCF have been widely adopted into clinical use since their
introduction. This review examines our single-center expe-
rience with the use of both R-VCF and P-VCF, with
particular emphasis on complications associated with their
use.
METHODS
Study group identification. After approval by the
Institutional Review Board at Wake Forest University
School of Medicine, all individuals undergoing VCF place-
ment between January 2000 and December 2004 were
identified by computerized search by using Current Proce-
dural Terminology code 37620.
Data collection and management. Identified patient
records were reviewed, including hospital charts, outpa-
tient clinic notes, operative reports, interventional radiol-
ogy reports, and noninvasive vascular laboratory records.
Data abstracted included patient demographics, medical
comorbidities, indication for VCF placement, procedural
details, type of VCF inserted, and postinsertion complica-
tions. VCFs were classified as P-VCFs (Over-the-Wire
Greenfield [Boston Scientific, Natick, Mass], Simon Niti-
nol [Bard, Tempe, Ariz], TrapEase [Cordis,Miami, Fla], or
Vena-Tech [B. Braun Medical, Evanston, Ill]) or R-VCFs
(OptEase Retrievable Vena Cava Filter [Cordis], Günther-
Tulip [Cook, Bloomington, Ind], or Recovery [Bard]).
Complications were defined according to the “Recom-
mended Reporting Standards for Vena Caval Filter Place-
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patients was based on clinical records from theWake Forest
University Baptist Medical Center electronic medical
record. Patients who underwent filter insertion at the study
institution but had no interval assessment or follow-up in
the medical record (n  50) were excluded from analysis.
Abstracted clinical data were entered into a deidentified
electronic database before statistical analysis.
End-point definition. The following end points were
considered to assess for complications: Vena cava thrombo-
sis was defined as clinically apparent occlusion of the vena
cava at any site and time during follow-up. Significant
bleeding was defined as blood loss necessitating transfusion
or prolongation of hospital stay after VCF placement. VCF
migration was defined as any clinically apparent change in
filter position from an infrarenal position to a perirenal or
suprarenal position.
Statistical methods. Demographic and procedural
data were summarized by using counts and percentages or
means  SD. Associations were evaluated for statistical
significance by using the Student t test for continuous data
and the Fisher exact test for categorical data as a result of
low expected cell counts. These data were analyzed with
SAS statistical software (version 9.1; SAS Institute, Inc,
Cary, NC). The significance level was set at P  .05.
RESULTS
Study group. A total of 239 VCFs were inserted
during the study period (213 P-VCFs and 26 R-VCFs).
Follow-up data were available for 189 patients (including
165 P-VCF and 24 R-VCF patients), and this latter group
constitutes the study sample for this report. Study sample
demographics and medical comorbidities are presented in
Table I. Compared with patients who had P-VCFs placed,
the group receiving R-VCFs was predominantly female
(62.5% vs 30.3%), had a larger proportion of patients with
both malignancy (41.7% vs 20%) and morbid obesity (25%
vs 4.2%), and had a lower proportion of patients with
paraplegia (0% vs 26.1%). Indications for VCF placement
are presented in Table II. The most frequent indication for
VCF placement was VTE with a contraindication to anti-
coagulation in both groups (n  117). Other indications
included VTE with failure of anticoagulation (n  12),
prophylaxis in the absence of VTE in the setting of multi-
system trauma (n  49) or surgery (n  8), and filter
insertion before catheter-directed thrombolysis (n  3). A
significant relationship was observed between placement of
a P-VCF vs an R-VCF and an indication for VCF insertion
(P  .001; Fisher exact test). More specifically, P-VCFs
were used nearly exclusively for prophylaxis in the setting of
multisystem trauma (48 [29%] P-VCF vs 1 [4.2%] R-VCF),
whereas R-VCF predominated among patients receiving
filters for surgical prophylaxis (6 [25%] R-VCF vs 2 [1.2%]
P-VCF) and catheter-directed thrombolysis (3 [12.5%]
R-VCF vs 0 P-VCF).
Procedural data. A summary of inserted filters by type
is presented in Table III. The most commonly placed
P-VCF was the Greenfield Over-the Wire filter, and themost commonly placed R-VCF was the OptEase filter.
Among patients receiving R-VCF, appropriate patients
were assessed for device retrieval at the earliest conclusion
of the period of increased risk for VTE and/or contraindi-
cation to anticoagulation. For the R-VCF group, retrieval
was attempted in 11 (46%) of 24 patients and was successful
in 9 patients at a median of 15 days. Planned retrieval was
unsuccessful in 2 (18%) of 11 attempts because of an
inability to visualize a Recovery VCF in a morbidly obese
patient and termination of planned retrieval after visualiza-
tion of extensive thrombus within a Günther-Tulip VCF;
this latter patient was treated with anticoagulation. The
remaining R-VCFs (n 13) were intentionally left in place
Table I. Demographics and comorbidities by filter type
Variable
All VCF
(n  189)
P-VCF
(n  165)
R-VCF
(n  24)
Age (y) 51.1  18.9 50.8  19.2 53.5  17.1
Sex*
Male 124 (65.6) 115 (69.7) 9 (37.5)
Female 65 (34.4) 50 (30.3) 15 (62.5)
Race
White 158 (83.6) 136 (82.4) 22 (91.7)
Black 27 (14.3) 25 (15.2) 2 (8.3)
Hispanic 4 (2.1) 4 (2.4) 0 (0.0)
Active malignancy* 43 (22.8) 33 (20.0) 10 (41.7)
Coronary artery
disease 56 (29.6) 47 (28.5) 9 (37.5)
Tobacco use 36 (19.1) 32 (19.4) 4 (16.7)
Defined
hypercoagulable
state 6 (3.2) 4 (2.4) 2 (8.3)
Paraplegia* 43 (22.8) 43 (26.1) 0 (0.0)
Morbid obesity* 13 (6.9) 7 (4.2) 6 (25.0)
Anticoagulation
Prophylactic 69 (36.5) 65 (39.4) 4 (16.7)
Therapeutic 20 (10.6) 16 (9.7) 4 (16.7)
None 100 (52.9) 84 (50.9) 16 (66.7)
VCF, Vena cava interruption filter; P-VCF, permanent vena cava filter;
R-VCF, removable vena cava filter.
*P  .05 for removable indicator vs demographic variable.
Table II. Indications for VCF placement
Indication*
All VCF
(n  189)
P-VCF
(n  165)
R-VCF
(n  24)
VTE with contraindication
to anticoagulation 117 (61.9) 106 (64.2) 11 (45.8)
VTE with failure of
anticoagulation 12 (6.4) 9 (5.5) 3 (12.5)
Prophylaxis: surgical
procedure 8 (4.2) 2 (1.2) 6 (25.0)
Prophylaxis: multiple
system trauma 49 (25.9) 48 (29.1) 1 (4.2)
Lysis 3 (1.6) 0 (0.0) 3 (12.5)
VCF, Vena cava interruption filter; P-VCF, permanent vena cava filter;
R-VCF, removable vena cava filter; VTE, venous thromboembolism.
Data are n (%).
*P  .05 for removable device vs all indications (Fisher exact test).because of ongoing contraindications to anticoagulation
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ulation (n  5), or patient death (n  3).
Follow-up and adverse events. Over a median clini-
cal follow-up of 8.5 months (interquartile range, 15.5
months), four adverse events (all vena cava thromboses)
were observed. No case of clinically apparent filter migra-
tion or significant perioperative hemorrhage was observed.
All patients with vena cava thrombosis were male. Three of
four vena cava thromboses occurred in patients who re-
ceived retrievable filters (P  .007; Fisher exact test). The
median time to thrombosis was 30.5 days. The US Food
and Drug Administration was notified of all vena cava
thrombosis cases during the preparation of this article.
The observed incidence of vena cava thrombosis with
each filter design is presented in Table III. All patients
with subsequent vena cava thrombosis had the same
indication for filter insertion: VTE with contraindication
to anticoagulation (n  4). The opposed biconical de-
sign shared by the removable OptEase and permanent
TrapEase VCF (Fig 1) was common to all filters associ-
ated with vena cava thrombosis.
Vena cava thrombosis occurred within a follow-up
range of 9 to 818 days, with a median time to thrombosis of
30.5 days, and was acutely symptomatic with massive limb
swelling in all patients. The only vena cava thrombosis–
related fatality presented with phlegmasia cerulea dolens
and abdominal compartment syndrome. This patient un-
derwent emergent surgical venous thrombectomy, lower-
extremity fasciotomies, and abdominal decompression be-
fore death. The other three cases were treated with
catheter-directed thrombolysis and rheolytic thrombec-
tomy (Angiojet System; Possis Medical, Minneapolis,
Minn), with successful re-establishment of caval flow, al-
though none had complete recanalization of the inferior
vena cava sufficient for filter removal. During the study
period, four additional patients with vena cava thrombosis
involving VCF placed at other medical facilities were
treated at our institution. All of these cases involved male
patients with acute clinical symptoms of phlegmasia, and all
had recently placed, prophylactic opposed biconical VCF
(One OptEase and Three TrapEase) before orthopedic
procedures. These cases were treated in a fashion compara-
Table III. Vena cava interruption filter type and
observed incidence of vena cava thrombosis (VCT)
Filter type n (col %) VCT (row %)
Permanent design
Greenfield 162 (85.7) 0 (0.0)
Vena-Tech 1 (0.5) 0 (0.0)
Simon Nitinol 1 (0.5) 0 (0.0)
TrapEase 1 (0.5) 1 (100.0)
Retrievable design
OptEase 13 (6.9) 3 (23.1)
Günther-Tulip 3 (1.6) 0 (0.0)
Recovery 8 (4.2) 0 (0.0)ble to the cases described previously and with similar re-sults. In no case was VCF removal possible, as a result of
residual caval thrombus.
DISCUSSION
This investigation details complications observed in a
single-center experience with both R-VCF and P-VCF.
Adverse events were uncommon, but thrombosis of the
inferior vena cava was observed more commonly than ex-
pected (given the small relative number of patients under-
going R-VCF vs P-VCF insertion in this cohort) and was
associated with severe clinical symptoms in all cases. Vena
cava thrombosis occurred more frequently in the presence
of R-VCF and was observed exclusively with a single design
among both permanent and retrievable devices: the op-
posed biconical configuration of theOptEase and TrapEase
filters.
Vena cava filters are designed to prevent fatal PE in
patients with contraindications to anticoagulation and re-
current PE despite therapeutic anticoagulation. Various
VCF designs exist. The gold standard filter is the stainless-
steel Greenfield filter introduced in 1973.8 The Greenfield
filter has been associated with excellent protection from
recurrent and fatal PE, and long-term follow-up studies
with the Greenfield filter have also demonstrated low rates
of adverse events, including vena cava thrombosis.9,10 Over
the past 20 years, multiple filter designs have been intro-
duced with hopes of improving on the results of the Green-
field filter or offering greater ease of introduction. More
recently, several filter designs have been introduced that
allow for VCF removal at some time distant from inser-
tion.11-13 The concept of VCF removal is attractive given
the temporary nature of the contraindication to anticoagula-
tion and/or the period of high risk for DVT inmany patients.
Retrievable devices currently available in the United States
include the Günther-Tulip and OptEase filters. Existing data
regarding R-VCFs suggest acceptable protection against PE
and a low incidence of adverse events.13-19 Reports of
adverse events after R-VCF insertion and/or retrieval exist,
with reported complications including vena cava thrombo-
sis, PE, bleeding, infection, and device migration or embo-
lization.20-22 No series detailing high rates of thrombosis
has been previously reported.
In the current series, vena cava thrombosis was ob-
served more frequently than expected. Cases of vena cava
thrombosis involving VCF placed at our institution in-
volved patients with VTE and contraindications to antico-
agulation (two patients with DVT and bleeding complica-
tions after therapeutic anticoagulation, one patient with
DVT and brain malignancy, and one patient with a history
of both DVT and PE who had a filter placed before a
planned hip-replacement operation). Referred cases of vena
cava thrombosis after VCF placement at another institution
during the study period (n  4) all involved prophylactic
filter placement before orthopedic surgical procedures. Po-
tential explanations for the high observed rate of thrombo-
sis include differences in device and patient selection crite-
ria, as well as factors related to filter design. Inferior vena
cava thrombosis after prophylactic filter insertion in the
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sizes the need for careful consideration and highly selective
use for this indication. The relatively limited experience
with temporary filters and the lack of data on their long-
term complications (including caval thrombosis) may war-
rant additional imaging surveillance, especially when they
are placed in a prophylactic scenario.
In this series, patients receiving P-VCF vs R-VCF dif-
fered in terms of both sex and several comorbidities (mor-
bid obesity, paraplegia, and malignancy; Table I). Among
these demographic characteristics, malignancy was more
common in patients receiving R-VCF and could be a pre-
disposing factor for thrombotic filter-related complica-
tions. However, in this series only one of eight observed
vena caval thromboses occurred in a patient with active
malignancy, thus making this explanation for the observed
findings unlikely. In addition to hormonal factors, the
female predominance in the R-VCF group is another pos-
sible explanation. However, no case of thrombosis was
observed among female patients in this series. Nonetheless,
a potential interaction between smaller inferior vena cava
diameter and device configuration may be worthy of fur-
ther investigation.
Indications for VCF insertion also differed between
groups (Table II), and this may reflect a selection prefer-
Fig 1. Vena cava thrombosis at the level of a biconica
and (B) partial recanalization after rheolytic mecha
thrombolysis.ence based on the previously named patient characteristics.These differencesmay reflect trends toward liberalization of
indications for caval filtration and preferential use of
R-VCF in select patient groups observed by others, partic-
ularly in the setting of multisystem trauma.22,23 Evidence-
based guidelines do not currently exist for the choice of
P-VCF vs R-VCF, however, and the use of a single set of
indications for caval interruption, regardless of the specific
device being considered, has been advocated.24 The pre-
dominance of R-VCF among patients experiencing vena
cava thrombosis in this series further emphasizes this point
and reinforces concerns over the increases in VCF use
observed since the introduction of retrievable devices. Ac-
cordingly, prophylactic VCF use in the trauma population
at our institution has remained selective and is limited to
multisystem trauma patients with spinal cord injury, paral-
ysis, contraindications to anticoagulation, and additional
risk factors for VTE. Because the duration of increased VTE
risk is temporally indistinct in this group (and in the ab-
sence of specific evidence for use of R-VCF), we have
elected to use P-VCF for select, very-high-risk patients.
Inherent design differences between filters may also
have contributed to the observed differences in thrombosis
rates, and we believe that these differences may be directly
related to filter structure more than removability per se.
This is supported by the fact that all observed caval throm-
r: (A) initial venography at time of catheter insertion
thrombectomy and 12 hours of catheter-directedl filte
nicalboses (both among devices inserted at our center and
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insertion at another institution) involved the opposed bi-
conical design (OptEase and TrapEase) VCFs. As initially
suggested by the in vitro studies of Leask et al,25 we
speculate that the inverted conical design (Fig 1) of these
filters marginates captured thrombus to the wall of the cava
where flow is the lowest and may predispose to thrombosis.
This margination effect may limit the exposure of the
thrombus to intrinsic thrombolytic mechanisms, thus lead-
ing to a narrowed aperture of the patent cava that can be
sequentially reduced by the centripetal accumulation of
additional thrombus. A margination effect would not be
operative in the single-cone design of the Greenfield, Re-
covery, Simon Nitinol, and Günther-Tulip filters, which
should direct captured thrombus to a central location of
higher relative blood flow. These hypotheses are consistent
with previous investigations of the relationships between
filter design, caval flow patterns, and thrombogenicity.25-27
Alternatively, the TrapEase and OptEase designs may be
more effective at capturing migrating thrombus, thus lead-
ing to a higher incidence of thrombosis. This notion would
be supported if a higher incidence of clinically apparent
recurrent PE were suspected or observed with the nonmar-
ginating designs. Unfortunately, our data sources do not
allow for an adequate examination of this potential expla-
nation. Although the vena cava thrombosis rates for the
biconical filter designs were remarkably high in this series
(4/14, or 28.6%), others have reported much lower inci-
dences of 0% to 1% with these devices.15,17,28,29 Potential
explanations for these discordant results include differences
in patient populations, selection criteria for VCF insertion,
duration of follow-up, management of anticoagulation,
and technical factors.
This investigation poses interesting findings with rele-
vance to VCF selection, but it also possesses several inher-
ent limitations that deserve comment. This study was a
retrospective investigation of complications observed after
VCF placement. As such, it is subject to numerous biases
and limitations in follow-up. In this cohort, vena cava
thromboses were detected as the result of clinical events;
lack of proscribed imaging studies to screen for this com-
plication may have resulted in an underestimation of its
incidence as a result of missed events occurring in the
absence of overt clinical manifestations. After placement of
P-VCF, long-term clinical follow-up was usually not sched-
uled with the surgical provider and consequently was more
limited in this group. Many of these patients were returned
to the care of their referring physicians without further
contact with our health system; anticoagulation status and
incidence of other thromboembolic events therefore could
not be reliably determined among these patients. The
R-VCF patients were more closely followed up, at least in
part because of plans for timely removal of the device.
These unavoidable biases could have led to underestima-
tion of complications in the P-VCF group. This potential is
somewhat mitigated by the fact that we represent the
primary academic tertiary care center in our referral region,
and it is unlikely that a clinically significant inferior venacava occlusion would have been treated without referral to
our center. Another potential limitation is the small num-
ber of VCF procedures reviewed, especially in the case of
the R-VCF. This small number could potentially lead to
erroneous overestimation of complication incidence given
the small sample size. However, this seems unlikely if the
complication of vena cava thrombosis is assumed to be a
rare event. A final limitation that must be mentioned is the
fact that the small numbers of observed complications,
although worrisome, precluded intensive analyses of ad-
verse outcomes. These combined limitations prohibit the
generation of evidence-based recommendations based on
these data.
Notwithstanding these limitations, this article describes
a higher-than-expected incidence of complications after
R-VCF placement. All observed complications were throm-
botic and associated with severe symptoms. Vena cava
thrombosis was limited to patients in whom the opposed
biconical VCF designs were placed. These findings have led
our group to be very cautious in the application of R-VCF
and to eliminate use of the opposed biconical VCF designs.
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